(Q40109282)

17 September 2017

title

Predictive tests for individualization of pharmacological cancer treatment (English)

1 reference

17 September 2017

2

Rolf Larsson

1 reference

17 September 2017

1

Peter Nygren

1 reference

17 September 2017

language of work or name

English

0 references

publication date

1 April 2008

1 reference

Expert Opinion on Medical Diagnostics

17 September 2017

published in

1 reference

17 September 2017

volume

2

1 reference

17 September 2017

issue

4

1 reference

17 September 2017

page(s)

349-360

1 reference

What is cancer chemotherapy?

17 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2.4.349

Individualized chemotherapy treatment for breast cancer: is it necessary? Is it feasible?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2.4.349

Genomic strategies for personalized cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2.4.349

Overview of the clinical efficacy of investigational anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2.4.349

Is tailored therapy feasible in oncology?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2.4.349

Cancer biomarkers--an invitation to the table

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2.4.349

Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2.4.349

Is molecular profiling ready for use in clinical decision making?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2.4.349

Biomarkers in cancer staging, prognosis and treatment selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2.4.349

Development and Validation of Biomarker Classifiers for Treatment Selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2.4.349

The relationship between prognostic and predictive factors in the management of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2.4.349

Assessing the clinical impact of prognostic factors: when is "statistically significant" clinically useful?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2.4.349

Clinical trial designs for predictive marker validation in cancer treatment trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2.4.349

Uses and abuses of tumor markers in the diagnosis, monitoring, and treatment of primary and metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2.4.349

The US Food and Drug Administration perspective on cancer biomarker development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2.4.349

Clinical trial design for microarray predictive marker discovery and assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2.4.349

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2.4.349

Chips to bedside: incorporation of microarray data into clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2.4.349

Molecular evidence-based medicine: evolution and integration of information in the genomic era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2.4.349

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2.4.349

The value of estrogen and progesterone receptor determinations in advanced breast cancer. Estrogen receptor level but not progesterone receptor level correlates with response to tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2.4.349

Predictive markers in breast and other cancers: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2.4.349

What clinicians need to know about antioestrogen resistance in breast cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2.4.349

Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2.4.349

Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2.4.349

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2.4.349

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2.4.349

Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2.4.349

BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2.4.349

Gastrointestinal stromal tumour.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2.4.349

Imatinib combined chemotherapy for Philadelphia chromosome-positive acute lymphoblastic leukemia: major challenges in current practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2.4.349

Rituximab therapy in malignant lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2.4.349

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2.4.349

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2.4.349

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2.4.349

Erlotinib in lung cancer - molecular and clinical predictors of outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2.4.349

Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2.4.349

Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2.4.349

American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2.4.349

Chemotherapy sensitivity and resistance testing: to be "standard" or to be individualized, that is the question

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2.4.349

Increased in vitro cellular drug resistance is related to poor outcome in high-risk childhood acute lymphoblastic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2.4.349

Review of the efficacy of individualized chemotherapy selected by in vitro drug sensitivity testing for patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2.4.349

Chemotherapy sensitivity and resistance assays: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2.4.349

Genomic and proteomic technologies for individualisation and improvement of cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2.4.349

Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2.4.349

A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2.4.349

Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2.4.349

An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2.4.349

Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2.4.349

Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2.4.349

Why most published research findings are false

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2.4.349

Genomic signatures to guide the use of chemotherapeutics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2.4.349

A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2.4.349

Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2.4.349

Proteomics in cancer research: methods and application of array-based protein profiling technologies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2.4.349

Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2.4.349

Revealing targeted therapy for human cancer by gene module maps.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2.4.349

21 January 2018

Identifiers

DOI

10.1517/17530059.2.4.349

1 reference

17 September 2017

1 reference